Literature DB >> 26922135

Distinct antibody species: structural differences creating therapeutic opportunities.

Serge Muyldermans1, Vaughn V Smider2.   

Abstract

Antibodies have been a remarkably successful class of molecules for binding a large number of antigens in therapeutic, diagnostic, and research applications. Typical antibodies derived from mouse or human sources use the surface formed by complementarity determining regions (CDRs) on the variable regions of the heavy chain/light chain heterodimer, which typically forms a relatively flat binding surface. Alternative species, particularly camelids and bovines, provide a unique paradigm for antigen recognition through novel domains which form the antigen binding paratope. For camelids, heavy chain antibodies bind antigen with only a single heavy chain variable region, in the absence of light chains. In bovines, ultralong CDR-H3 regions form an independently folding minidomain, which protrudes from the surface of the antibody and is diverse in both its sequence and disulfide patterns. The atypical paratopes of camelids and bovines potentially provide the ability to interact with different epitopes, particularly recessed or concave surfaces, compared to traditional antibodies.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26922135      PMCID: PMC4884505          DOI: 10.1016/j.coi.2016.02.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  62 in total

Review 1.  Adverse reactions to snake antivenom, and their prevention and treatment.

Authors:  H Asita de Silva; Nicole M Ryan; H Janaka de Silva
Journal:  Br J Clin Pharmacol       Date:  2015-09-16       Impact factor: 4.335

Review 2.  Fully human antibodies from transgenic mouse and phage display platforms.

Authors:  Nils Lonberg
Journal:  Curr Opin Immunol       Date:  2008-07-21       Impact factor: 7.486

3.  General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold.

Authors:  Cécile Vincke; Remy Loris; Dirk Saerens; Sergio Martinez-Rodriguez; Serge Muyldermans; Katja Conrath
Journal:  J Biol Chem       Date:  2008-11-14       Impact factor: 5.157

4.  Modulation of protein properties in living cells using nanobodies.

Authors:  Axel Kirchhofer; Jonas Helma; Katrin Schmidthals; Carina Frauer; Sheng Cui; Annette Karcher; Mireille Pellis; Serge Muyldermans; Corella S Casas-Delucchi; M Cristina Cardoso; Heinrich Leonhardt; Karl-Peter Hopfner; Ulrich Rothbauer
Journal:  Nat Struct Mol Biol       Date:  2009-12-13       Impact factor: 15.369

5.  Research strategies to improve snakebite treatment: challenges and progress.

Authors:  Robert A Harrison; Darren A Cook; Camila Renjifo; Nicholas R Casewell; Rachel B Currier; Simon C Wagstaff
Journal:  J Proteomics       Date:  2011-06-25       Impact factor: 4.044

6.  TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation.

Authors:  M L V Hendrickx; A DE Winter; K Buelens; G Compernolle; G Hassanzadeh-Ghassabeh; S Muyldermans; A Gils; P J Declerck
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

7.  Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition.

Authors:  David Oyen; Vasundara Srinivasan; Jan Steyaert; John N Barlow
Journal:  J Mol Biol       Date:  2011-01-14       Impact factor: 5.469

8.  Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies.

Authors:  Erwin De Genst; Karen Silence; Klaas Decanniere; Katja Conrath; Remy Loris; Jörg Kinne; Serge Muyldermans; Lode Wyns
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

9.  Tetrameric and homodimeric camelid IgGs originate from the same IgH locus.

Authors:  Ikbel Achour; Patricia Cavelier; Magali Tichit; Christiane Bouchier; Pierre Lafaye; François Rougeon
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

10.  Crystal structure of the β2 adrenergic receptor-Gs protein complex.

Authors:  Søren G F Rasmussen; Brian T DeVree; Yaozhong Zou; Andrew C Kruse; Ka Young Chung; Tong Sun Kobilka; Foon Sun Thian; Pil Seok Chae; Els Pardon; Diane Calinski; Jesper M Mathiesen; Syed T A Shah; Joseph A Lyons; Martin Caffrey; Samuel H Gellman; Jan Steyaert; Georgios Skiniotis; William I Weis; Roger K Sunahara; Brian K Kobilka
Journal:  Nature       Date:  2011-07-19       Impact factor: 49.962

View more
  19 in total

1.  Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature.

Authors:  Roshank Ahani; Farzin Roohvand; Reza Ahangari Cohan; Mohammad Hossein Etemadzadeh; Nasir Mohajel; Mahdi Behdani; Zahra Shahosseini; Navid Madani; Kayhan Azadmanesh
Journal:  Mol Biotechnol       Date:  2016-11       Impact factor: 2.695

2.  Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.

Authors:  Julia Hambach; William Fumey; Tobias Stähler; Anna Josephine Gebhardt; Gerhard Adam; Katja Weisel; Friedrich Koch-Nolte; Peter Bannas
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

3.  Gene prediction in the immunoglobulin loci.

Authors:  Vikram Sirupurapu; Yana Safonova; Pavel A Pevzner
Journal:  Genome Res       Date:  2022-05-11       Impact factor: 9.438

Review 4.  Engineered Autonomous Human Variable Domains.

Authors:  Johan Nilvebrant; Peter M Tessier; Sachdev S Sidhu
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 5.  Bos taurus ultralong CDR H3 antibodies.

Authors:  Melissa L Vadnais; Vaughn V Smider
Journal:  Curr Opin Struct Biol       Date:  2016-06-10       Impact factor: 6.809

Review 6.  Escherichia coli surface display for the selection of nanobodies.

Authors:  Valencio Salema; Luis Ángel Fernández
Journal:  Microb Biotechnol       Date:  2017-08-03       Impact factor: 5.813

Review 7.  Nanobodies As Tools to Understand, Diagnose, and Treat African Trypanosomiasis.

Authors:  Benoit Stijlemans; Patrick De Baetselier; Guy Caljon; Jan Van Den Abbeele; Jo A Van Ginderachter; Stefan Magez
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

8.  Intracellular Crosslinking of Filoviral Nucleoproteins with Xintrabodies Restricts Viral Packaging.

Authors:  Tamarand Lee Darling; Laura Jo Sherwood; Andrew Hayhurst
Journal:  Front Immunol       Date:  2017-09-27       Impact factor: 7.561

9.  Targeted antigen delivery by an anti-class II MHC VHH elicits focused αMUC1(Tn) immunity.

Authors:  Tao Fang; Catharina H M J Van Elssen; Joao N Duarte; Jonathan S Guzman; Jasdave S Chahal; Jingjing Ling; Hidde L Ploegh
Journal:  Chem Sci       Date:  2017-05-26       Impact factor: 9.825

Review 10.  Using cross-species vaccination approaches to counter emerging infectious diseases.

Authors:  George M Warimwe; Michael J Francis; Thomas A Bowden; Samuel M Thumbi; Bryan Charleston
Journal:  Nat Rev Immunol       Date:  2021-06-17       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.